In the past few years, a number of CTL-defined human tumor peptides have been identified, and attempts are being made for their clinical application. Consequently, preclinical CTL-defined peptide vaccine models are urgently needed to provide insights that might be translated into clinical applications. The Meth A sarcoma is one of the best studied murine tumors, and it is extremely lethal unless protective immunity is induced. A CD8+,H-2Kd-restricted anti-Meth A CTL line has been isolated, and shown by adoptive transfer capable of eradicating Meth A lung metastases. This result confirms the functional role of the epitope in tumor rejection. We have also shown that this epitope is derived from Meth A gp110, a glycoprotein with proven tumor rejection-inducing activity. Independently, a fraction of H-2Kd-associated Meth A peptides was shown to contain the CTL-defined epitope. We are currently using mass spectral (MS) analysis of this peptide fraction as well as information obtained from the isolation and sequence analysis of cDNA encoding Meth A gp110 to identify the CTL-defined Meth A epitope. A critical aspect of peptide-based vaccine development is identification of adjuvants, chemical or cellular, which permit induction of anti- peptide CTL. We have modified published methods for generating bone marrow(BM)derived dendritic cells (DC), which has permitted us to demonstrate the efficacy of peptide-pulsed DC vaccines in two, well- characterized CTL-defined peptide models. In a human papilloma virus type16 E7-peptide model, we have also demonstrated the beneficial effect of administration of E7-pulsed DC on mice bearing 14-day old, locally growing tumors. The evidence of the expression in some human tumors of the human counterpart of Meth A gp110 points to the direct extension of our analysis of Meth A gp110 to clinical studies, and the potentially broad and clinically relevant aspects of our efforts to identify the CTL- defined tumor antigens of the chemically induced BALB/c Meth A and CMS4 sarcomas.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA064623-03
Application #
2700571
Study Section
Experimental Immunology Study Section (EI)
Program Officer
Hecht, Toby T
Project Start
1996-05-01
Project End
2000-04-30
Budget Start
1998-05-15
Budget End
2000-04-30
Support Year
3
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Visus, Carmen; Wang, Yangyang; Lozano-Leon, Antonio et al. (2011) Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8? T cells. Clin Cancer Res 17:6174-84
Dworacki, Grzegorz; Cicinnati, Vito R; Beckebaum, Susanne et al. (2005) Unpulsed dendritic cells induce broadly applicable anti-tumor immunity in mice. Cancer Biol Ther 4:50-6
Cicinnati, Vito R; Dworacki, Grzegorz; Albers, Andreas et al. (2005) Impact of p53-based immunization on primary chemically-induced tumors. Int J Cancer 113:961-70
Gambotto, A; Dworacki, G; Cicinnati, V et al. (2000) Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope. Gene Ther 7:2036-40
Tuting, T; Gambotto, A; DeLeo, A et al. (1999) Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Ther 6:73-80
Tuting, T; Gambotto, A; Robbins, P D et al. (1999) Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen. Gene Ther 6:629-36
Tuting, T; DeLeo, A B; Lotze, M T et al. (1997) Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or ""self"" antigens induce antitumor immunity in vivo. Eur J Immunol 27:2702-7